Hearing loss in infants with persistent fetal circulation.
Infants with the diagnosis of persistent fetal circulation were evaluated for hearing loss. From Jan 1, 1982, to Jan 1, 1984, 28 infants with this diagnosis were retrospectively identified, and 18 were evaluated by formal audiologic testing. Additionally, 22 infants were prospectively followed by serial auditory evaluation from Jan 1, 1984, to Jan 1, 1986. Of the 40 infants evaluated, 21 were identified as having hearing impairment (52.5%), 14 of whom required hearing aids. For 82% of those retrospectively identified hearing-impaired infants who required hearing aids, parental concern was expressed for their lack of hearing acuity. This factor could have aided in the earlier recognition of these infants' impairment. Among those infants followed prospectively, formal audiologic testing, in some cases serially, was needed to diagnose a progressive hearing loss that was expressed at 6 to 8 months after discharge from the neonatal intensive care unit. Perinatal factors associated with the development and management of persistent fetal circulation were identified and compared in infants with confirmed hearing loss and those with normal hearing. Variables related to those infants with hearing loss were as follows: degree of alkalosis, duration of ventilation, and possibly use of furosemide. We concluded from these results that infants with persistent fetal circulation have an extremely high incidence of sensorineural hearing loss and suggest serial formal audiologic evaluations to aid in detection of hearing-impaired infants.
D002658:Developmental Disabilities / Q000209:etiology; D005665:Furosemide / Q000009:adverse effects; D006310:Hearing Aids; D006319:Hearing Loss, Sensorineural / Q000175:diagnosis / Q000209:etiology* / Q000534:rehabilitation; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008471:Meconium Aspiration Syndrome / Q000150:complications; D010547:Persistent Fetal Circulation Syndrome / Q000150:complications*; D012121:Respiration, Artificial / Q000009:adverse effects
D005665:Furosemide